Antares' (ATRS) Vibex QuickShot auto injector restored and maintained testosterone levels in a Phase II study of 29 patients. The testosterone-replacement market was worth $2.8B in sales in 2013.
Independent analysis examines Fridays' published TRT program structure, delivery format options, and what clinical research indicates for men evaluating prescription testosterone pathways heading into ...
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ:ATRS) today announced that a meeting was held with the U.S. Food and Drug Administration (FDA) to discuss a registration study for the VIBEX ...
EWING, N.J., May 16, 2017 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) announced that data from its Phase 3 study of the pharmacokinetics and safety of subcutaneous testosterone enanthate ...
Xyosted carries a Boxed Warning regarding blood pressure increases that may potentially increase the risk for major adverse cardiovascular events. The Food and Drug Administration (FDA) has approved ...
Aurobindo Pharma’s subsidiary, Eugia Pharma Specialities, has received the Food and Drug Administration’s permission for Testosterone Cypionate Injection 1,000 mg/10 ml (100 mg/ml) and 2,000 mg/10 ml ...
Testosterone injections are a treatment for sexual dysfunction in males and for low testosterone in either males or females. They can also be part of gender affirming care. Although testosterone ...
The auto injector market represents a rapidly expanding segment within the global pharmaceutical delivery systems industry, driven by the increasing prevalence of chronic diseases and the growing ...
(MENAFN- GlobeNewsWire - Nasdaq) Independent analysis examines Fridays' published TRT program structure, delivery format options, and what clinical research indicates for men evaluating prescription ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback